4th Annual - Diabetes Conference 2008 - 18th To 20th February 2008, London
Once again, the Advances in Diabetic Therapeutics conference brings together all the leading players in diabetes drug development. Our top speakers will help you to evaluate the limitations of existing diabetes therapies. They will assist you in identifying where new advances are being made, and which approaches are best for you and your pipeline.The market for treatment of diabetes and metabolic syndrome is growing exponentially. You and your organisation should be prepared for this. By attending this unique event, you will be.
Top Quality Speakers Include:
- Dr David Gillen, Medical Director,Pfizer
- Dr Richard Carr, Senior Director, Merck
- Dr Timothy Herpin, Director, Metabolic Disease Licensing, Bristol-Myers Squibb
- Dr Annette M. Perregaard, Licensing Director, Novo Nordisk
- Dr Martin Shaw, Senior Product Manager, Biotrin International
- Dr Itzik Harosh, Founder and CSO, Obe Therapy
- Dr Dana Elias, VP Program Director, Andromeda Biotech
- Dr Krishna Prasad, Medicines and Healthcare products Regulatory Agency, Department
- Dr Roger New, C-Founder and R&D Director, Proxima Concepts
- Professor Steve Bloom, FMedSci Professor Division of Investigative Science, Imperial College
- Dirk Kars, Partner, Simon-Kucher & Partners
- Professor David Heal, Director, RenaSci Consultancy
- Nick Hughes, Head of Life Sciences & Healthcare Practice, PA Consulting Group
-Dr William Valentine, Director, IMS Health Economics and Outcomes Research
The market for treatment of metabolic diseases is growing exponentially where the market to treat metabolic syndrome is projected to nearly double to almost $18 Billion by 2014. Unmet clinical need in developed markets and a rapidly-expanding market in emerging economies will drive market growth in diabetes. One of the most important co-factors in the development of diabetes is an expanding patient population due to increasing obesity and an ageing population, the predicted market in 2011 is expected to reach a total value of just over $21bn.
The emergence of new delivery technology will also be a significant driver of the world diabetes treatment market. Equally significant has been the introduction of two new classes of drugs. The GLP-l agonists and DPP-lV inhibitors introduce a new approach, while delivery technology continues to play a role. Some of the fastest growing markets for diabetes are in the emerging economies such as India, China and Indonesia, which are in the top 5 for disease prevalence. The impact for both branded and generic drugs is considerable in the diabetic therapeutic market.
Key topic areas at this conference include:
- Enhancement of Insulin delivery through innovative and improved insulin delivery methods (Insulin pens, jet injectors, external insulin pumps, injections, oral sprays, insulin pills, transdermal patches and inhalators)
- Targeting symptoms of metabolic syndrome and preventive measures to achieve a decrease in diabetes prevalence
- Continued market penetration of non-insulin and oral anti-diabetes therapies of heightening insulin sensitivity
- Impact from trends in pricing and re-imbursement on the market for diabetes treatments
- Research on the mechanism of action behind resistance and on the most relevant compounds currently in clinical trials
Pre-Conference Workshop, Monday 18th February 2008
Developing a sustainable pricing and reimbursement strategy for your innovation in diabetes
Workshop Leader - Christian Schuler, Director, Life Science Division, Simon-Kucher & Partners
Led by:
Michael Bartram ,Senior Consultant Simon-Kucher & Partners
Dr. Florian Sauer, Senior Consultant Simon-Kucher & Partners
Timings:
09:30 - 10:00 Coffee & Registration
10:00 - 15:00 Workshop
Timing includes lunch and refreshment breaks
Key Topics:
Developing a sustainable pricing and reimbursement strategy for your innovation in diabetes
- Diabetes - A ticking time bomb for payers
- What payers want in the area of diabetes - Innovation as the basis of successful pricing
- Latest trends in European payer policies
- Latest experiences from new products launches in diabetes
- Critical success factors for market access, pricing and reimbursement in diabetes
- How to price your product right - the concept of value-based pricing
This Conference will bring together market leaders, specialists and renowned academics to:
- Hear strategies for overcoming the limitations of current therapies
- Discover the latest innovations in intersection of obesity, macronutrient regulation and Type 1 and 2 diabetes
- Keep up to date with launched drugs such as GLP-I agonists and DDP-IV inhibitors
- Understand how combination therapies will play their part in the future as will novel drug delivery technologies
- Identify the most promising new pathways from lab investigations
- Focusing to make the right strategic alliances
- Use antisense technology to discover new diabetes drugs
Conference Agenda
Day One, Tuesday 19th February 2008
09:00 Registration and refreshments
09:30 Opening address from the chair
09:40 Exploring diabetes licensing landscape and deal making trends
- Recent deals and collaborations in the diabetes and obesity area
- Licensing landscape: technologies and compounds
- Trends in the financing and strategic development of diabetes biotech companies
Dr Timothy Herpin,Director, Metabolic Disease Licensing,Bristol-Myers Squibb
10:20 The use of system dynamic modelling in understanding the intervention opportunities in diabetes and its associated comorbidities
- The diabetic population and the interaction with other conditions and comorbidities
- The ability to understand how different interventions will impact the diabetic population
- Insights learned from the uset
Nick Hughes,Head of Life Sciences & Healthcare Practice,PA Consulting Group
11:00 Morning refreshments
11:20 Autoimmune diabetes: How can it be stopped?
- The first drug to stop the destruction of the pancreatic beta cells in humans
- How does the agent work
- Results of safety and efficacy phase II clinical studies
- Implications for the future management of autoimmune diabetes
Dr Dana Elias,VP, Program Director,Andromeda Biotech
12:00 Capsulin(TM) Oral Insulin
- Results of Phase II trials
- Type I and Type II data - multiple dose
- Advantage of liver delivery
- Improvement of glucose control
Dr Roger New,Co-Founder and R&D Director,Diabetology
12:40 Networking lunch
13:40 Fighting diabetes Type 2 with 'Expenditure Genes'
- Is diabetes Type 2 a disease or a consequence? Are we treating the symptoms or the disease?
- The paradox; why some obese people do not develop diabetes and why some lean individuals do
- A new approach for identifying genes for diabetes treatment
- A drug versus work-out regime
Dr Itzik Harosh,Founder and CSO,Obe Therapy
14:20 Challenges for licensing diabetes technologies in current pharmaceutical environment
- OADs vs protein-based technologies
- Improvements vs innovation
- Source of innovation
Dr Annette M. Perregaard,Licensing Director,Novo Nordisk
15:00 Afternoon refreshments
15:20 Demonstrating the economic and humanistic benefits of modern diabetes therapies
Dr William Valentine,Director,IMS Health Economics and Outcomes Research
16:00 Regulatory issues related to newer treatment developments in diabetes
- Regulatory requirements and relevant European guidelines
- Complexities of antidiabetic treatments and regulatory challenges
- Impact of emerging information/data in relation to newer developments
Dr Krishna Prasad,Medicines and Healthcare products Regulatory Agency,Department of Health
16:40 Exploring biomarkers of Diabetic nephropathy
- The problem of diabetic nephropathy
- Improved monitoring of renal injury in diabetics by specific biomarkets
Dr Martin Shaw,Senior Product Manager,Biotrin International
17:20 Closing remarks from the chair
17:25 Networking Drinks Reception
Day Two, Wednesday 20th February 2008
09:00 Registration and refreshments
09:30 Opening address from the chair
Dr David Gillen,Medical Director,Pfizer
09:40 Treatment of sight threatening diabetic retinopathy
- Diabetes epidemic is a global threat with the number expected to rise to a staggering 350 million by 2025.
- People with diabetes are at risk of losing sight due to DR, a leading cause of blindness in people of the working age
- At present there is no cure. For sight threatening DR, laser treatment (photocoagulation) and vitrectomy are currently used to improve vision
- New and better therapies are now emerging to help preserve sight in the growing population of diabetic patients into the 21st century
Dr Rakesh Chibber,Peninsula College of Medicine and Dentistry,Peninsula Medical School
10:20Examining examples in obesity therapy
- Diabetes causes 1,000 deaths per week in the UK
- The only effective current treatment is gut bypass surgery
- Most proposed drug therapies are ineffective or dangerous
- What is the possible way forward?
Professor Steve Bloom,Department of Metabolic Medicine,Imperial College London
11:00 Morning refreshments
11:20 Metabolic Syndrome disorders in spinal injured persons: Incidence and long-term poly therapy management outcome
- Emphasises careful evaluation of each metabolic disorder in diabetics and aggressive management with polytherapy to expeditiously control all risk factors, in order to prevent negative cardiovascular outcomes
- This is particularly true for the spinal cord injury patients who are prone to a multitude of secondary complications of diabetes including repeated urinary tract infections, skin breakdown and ulceration and high cardiovascular morbidity and mortality
- Polytherapy management outcome will be presented
Dr Inder Perkash,Professor Urology, PVA Professor SCI Medicine, Director SCI Service,(emeritus) & Professor Orthopedic Surgery,Stanford University
12:00 Pricing & reimbursement for diabetes drugs in Europe
- The temparature is rising!
- How payers view diabetes
- What payers want
- Latest trends in pricing and reimbursement of diabetes products in the EU market environment
- How to successfully achieve market access for diabetes drugs in Europe
Dirk Kars,Partner,Simon-Kucher & Partners
12:40 Networking lunch
14:00 Overcoming challenges in the diabetes market
- Focus on diabetes as common, growing, costly and serious health problem
- Improving metabolic control and decrease complications
- Opportunities for better diabetes care?
- Advanced and effective treatment therapies
Dr David Gillen,Medical Director,Pfizer
14:40 Januvia: A scientific and medical update of a DPP-4 inhibitor
- Physiology of the DPP4 enzyme
- Cardiovascular effects of GLP-1
- Januvia: Scientific/Medical Update
Dr Richard David Carr,Senior Director,Merck
15:20 Afternoon refreshments
15:40 Is there a viable role for anti-obesity drugs in the treatment of Type 2 diabetes?
- The role of obesity as a key driver of the Type 2 diabetes epidemic.
- A realistic assessment of the contribution of moderate weight-loss to improving glycaemic control in diabetic patients.
- Combination therapy with anti-obesity and anti-diabetic drugs to maximize clinical benefit in the treatment of type 2 diabetes.
- Routes to regulatory approval for metabolic drugs
- obesity versus Type 2 diabetes
Professor David Heal,Director,RenaSci Consultancy
16:20 Chair's closing remarks
16:30 End of conference
***Booking your place***
2 day Conference ticket -
available for only GBP £1299
2 day Confernce ticket + worshop-
available for only GBP £1699
Registration is simple!
All you need to do to book your place is contact Justyna.
TEL: +44 (0)207 549 9946 or
email: justyna.drozdzal@visiongainglobal.com
Vision Gain LTD
4a anual - Diabetul zaharat de conferinte 2008 - Al 18-lea Pentru a 20-februarie 2008, Londra - 4th Annual - Diabetes Conference 2008 - 18th To 20th February 2008, London - articole medicale engleza - startsanatate